Omega‐3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non‐alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Omega‐3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non‐alcoholic fatty liver disease

Published:2021-10-07 Issue:11 Volume:35 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Camacho‐Muñoz Dolores¹^ORCID,Kiezel‐Tsugunova Magdalena¹,Kiss Orsolya¹,Uddin Mohib²,Sundén Mattias³,Ryaboshapkina Maria²,Lind Lars⁴,Oscarsson Jan²,Nicolaou Anna¹⁵

Affiliation:

1. Laboratory for Lipidomics and Lipid Biology Division of Pharmacy and Optometry School of Health Sciences Faculty of Biology, Medicine and Health University of ManchesterManchester Academic Health Science Centre Manchester UK

2. AstraZeneca Gothenburg, Biopharmaceuticals R&D Mӧlndal Sweden

3. Department of Economics University of Gothenburg Gothenburg Sweden

4. Department of Medical Sciences Uppsala University Uppsala Sweden

5. Lydia Becker Institute of Immunology and Inflammation Faculty of Biology, Medicine and Health The University of ManchesterManchester Academic Health Science Centre Manchester UK

Funder

AstraZeneca

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202100380RRR

Reference77 articles.

1. Hypertriglyceridemia: new approaches in management and treatment

2. Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

3. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases